OUR ASPIRATION: To become a leading LatAm biotech company delivering innovative treatments to patients with cancers, rare diseases and other specialty conditions
Hereditary angioedema is a rare genetic disorder characterized by severe episodic swelling due to accumulation of excessive body fluid (edema).
Duchenne muscular dystrophy is a rare and genetic disease characterized by progressive muscle weakness and degeneration/ loss (atrophy) of skeletal and cardiac muscles.
Fabry disease is a rare inherited lysosomal storage disorder that results from the accumulation of a specific type of fat in the body’s cells, called globotriaosyceramide (GL-3).
Myelodysplastic syndrome is a rare, heterogenous type of blood disorder that affects normal blood cell production in the bone marrow. Consequently,
Peripheral arterial disease characterizes a common circulatory problem caused by narrowed arteries that reduce blood flow to the limbs.
Congenital heart defects describe malformations of the heart that are existing at birth. Defects may involve the interior walls of the heart,
Pulmonary arterial hypertension (PAH) is a rare progressive disorder characterized by high blood pressure (hypertension) in the pulmonary arteries.
Pain defines a complex interaction between specialized nerves, the spinal cord and the brain. It is an important reaction of the nervous system which warns of possible injury.
Hematological disorders describe different kinds of pathological conditions that primarily affect the blood or blood-forming organs, e.g. red blood cells, white blood cells,
Peripheral T-cell lymphoma represents a rare aggressive (fast-growing) type of non-Hodgkin lymphoma, in which mature white blood cells, called T-cells,
Glioblastoma multiforme is the most common malignant and aggressive type of tumour that originates in the brain (primary brain tumour).
Chronic myeloid leukaemia is a type of cancer that affects the blood and bone marrow. In this condition the bone marrow produces too many granulocytes (white blood cells).
Located in the heart of Europe, Pint Pharma is well situated to service our global partners through our operational teams in Switzerland and Austria. We pride ourselves in providing exceptional expertise and know-how of the Latin American pharmaceutical industry, and strive to provide best-in-class treatment and service to the patient population through strategic alliances with our global business partners..
Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced it has entered into an exclusive license agreement with Pint Pharma for the commercialization of Beleodaq® (belinostat), Onxeo’s pan-HDAC inhibitor for PTCL (peripheral T-cell lymphoma), in key South American countries.
NEWTOWN, Pa., March 05, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS),
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pint Pharma International S.A., a company focused on innovative treatments for patients in Latin America with cancer, rare diseases, and genetic disorders, have entered into an agreement for Pint Pharma to commercialize NERLYNX® (neratinib)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (ARIAD; NASDAQ:ARIA) today announced that it has completed two distribution agreements for Iclusig® (ponatinib) outside of the United States. In Latin America, ARIAD and Pint Pharma International S.A., a company focused on innovative treatments for patients in Latin America with cancer, rare diseases, and genetic disorders,
If you or a person you know experiences any discomfort or adverse effect that may, or may not, have been caused by treatment with a Pint Pharma product, you can report it to us. Communication with our patients and health professionals who prescribe our medicines is very important to us.
To find the e-mail address for your country, click here.
Pint Pharma has its own pharmacovigilance system that monitors the safety and efficacy of our products when our patients are using them.
Si Ud. o una persona que conoce experimenta alguna molestia o efecto adverso que puede, o no, haber sido causado por el tratamiento con un producto Pint Pharma, puede informarnos lo sucedido. Es muy importante para nosotros la comunicación con nuestros pacientes y profesionales de la salud que prescriben nuestros medicamentos.
Para encontrar la dirección de correo electrónico correspondiente a su país, haga clic aquí.
Pint Pharma cuenta con su propio sistema de farmacovigilancia que monitorea la seguridad y eficacia de nuestros productos cuando nuestros pacientes los están usando.